Unknown

Dataset Information

0

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.


ABSTRACT: rifampicin lowers nevirapine plasma concentrations by inducing cytochrome P450. However, few data are available on this interaction during the lead-in period of nevirapine treatment.eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400). Subjects underwent 12 h intensive pharmacokinetic sampling on Days 7, 14 and 21 of nevirapine treatment. A minimum effective concentration (MEC) of 3000 ng/mL was used to interpret nevirapine concentrations 12 h after dosing (C(12)).NCT00617643 (www.clinicaltrials.gov).day 7 geometric mean nevirapine C(12) [90% confidence interval (CI)] was 1504 (1127-2115) ng/mL and 3148 (2451-4687) ng/mL in the NVP200 and NVP400 arms, respectively (P?

SUBMITTER: Lamorde M 

PROVIDER: S-EPMC3001850 | biostudies-literature | 2011 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Nevirapine pharmacokinetics when initiated at 200 mg or 400 mg daily in HIV-1 and tuberculosis co-infected Ugandan adults on rifampicin.

Lamorde Mohammed M   Byakika-Kibwika Pauline P   Okaba-Kayom Violet V   Ryan Mairin M   Coakley Peter P   Boffito Marta M   Namakula Rhoda R   Kalemeera Francis F   Colebunders Robert R   Back David D   Khoo Saye S   Merry Concepta C  

The Journal of antimicrobial chemotherapy 20101102 1


<h4>Background</h4>rifampicin lowers nevirapine plasma concentrations by inducing cytochrome P450. However, few data are available on this interaction during the lead-in period of nevirapine treatment.<h4>Methods</h4>eighteen HIV-1/tuberculosis co-infected adults receiving rifampicin daily as part of anti-tuberculosis therapy were evenly randomized to nevirapine initiation by dose escalation (NVP200) or nevirapine initiation at 200 mg twice daily (NVP400). Subjects underwent 12 h intensive pharm  ...[more]

Similar Datasets

| S-EPMC3594886 | biostudies-literature
| S-EPMC4744681 | biostudies-literature
| S-EPMC4701182 | biostudies-literature
| S-EPMC3594885 | biostudies-literature
| S-EPMC3465101 | biostudies-literature
| S-EPMC4176729 | biostudies-other
| S-EPMC5409034 | biostudies-literature
| S-EPMC4607735 | biostudies-literature
| S-EPMC8146561 | biostudies-literature
| S-EPMC2322990 | biostudies-literature